HomeCompareHKMPY vs SBUX

HKMPY vs SBUX: Dividend Comparison 2026

HKMPY yields 4.73% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HKMPY wins by $133.93M in total portfolio value
10 years
HKMPY
HKMPY
● Live price
4.73%
Share price
$35.06
Annual div
$1.66
5Y div CAGR
82%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$134.08M
Annual income
$121,431,071.65
Full HKMPY calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — HKMPY vs SBUX

📍 HKMPY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHKMPYSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HKMPY + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HKMPY pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HKMPY
Annual income on $10K today (after 15% tax)
$402.45/yr
After 10yr DRIP, annual income (after tax)
$103,216,410.90/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, HKMPY beats the other by $103,160,446.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HKMPY + SBUX for your $10,000?

HKMPY: 50%SBUX: 50%
100% SBUX50/50100% HKMPY
Portfolio after 10yr
$67.12M
Annual income
$60,748,455.89/yr
Blended yield
90.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

HKMPY
No analyst data
Altman Z
3.5
Piotroski
7/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HKMPY buys
0
SBUX buys
0
No recent congressional trades found for HKMPY or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHKMPYSBUX
Forward yield4.73%2.75%
Annual dividend / share$1.66$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR82%48.3%
Portfolio after 10y$134.08M$157.5K
Annual income after 10y$121,431,071.65$65,840.13
Total dividends collected$133.09M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: HKMPY vs SBUX ($10,000, DRIP)

YearHKMPY PortfolioHKMPY Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$11,562$861.72$11,107$407.21+$455.00HKMPY
2$14,066$1,694.64$12,512$626.87+$1.6KHKMPY
3$18,557$3,506.74$14,366$978.69+$4.2KHKMPY
4$27,725$7,869.35$16,929$1,557.50+$10.8KHKMPY
5$49,665$19,998.40$20,658$2,543.80+$29.0KHKMPY
6$114,074$60,932.92$26,406$4,302.22+$87.7KHKMPY
7$360,116$238,056.37$35,877$7,622.00+$324.2KHKMPY
8$1,663,594$1,278,270.23$52,741$14,352.64+$1.61MHKMPY
9$11,824,255$10,044,209.16$85,676$29,243.03+$11.74MHKMPY
10$134,083,024$121,431,071.65$157,513$65,840.13+$133.93MHKMPY

HKMPY vs SBUX: Complete Analysis 2026

HKMPYStock

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Full HKMPY Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this HKMPY vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HKMPY vs SCHDHKMPY vs JEPIHKMPY vs OHKMPY vs KOHKMPY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.